A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Divarasib (Primary) ; Adagrasib; Sotorasib
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms Krascendo 1
Sponsors Roche

Most Recent Events

11 Dec 2024 Planned primary completion date changed from 31 Jul 2026 to 23 Sep 2026.
30 Sep 2024 Planned End Date changed from 31 Jul 2028 to 30 Sep 2029.
06 Aug 2024 Planned initiation date changed from 25 Jul 2024 to 30 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight